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Box start 
What you need to know 
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Illicit opioid users have complex needs and require agencies to work collaboratively 
to help them access healthcare, education, employment, and housing  
 
Illicit opioid users may have multiple health problems associated with premature 
disability and mortality 
$GRSWDFRQVLVWHQWSURDFWLYHDQGQRQ-judgemental approach in all therapeutic 
contacts with opioid users to counter stigma and pessimism about effective 
treatment 
7UDLQSDWLHQWVDQGFDUHUVLQWKHILUVWUHVSRQVHWRRSLRLGRYHUGRVHLQFOXGLQJWKHXVH
of naloxone treatment kits 
/HQJWKRIWLPHLQWUHDWPHQW with opioid agonists is the strongest predictor of positive 
bio-psychosocial outcomes and reduces premature mortality 
Box end 
Use of illicit opioids, most commonly heroin, has a wide ranging impact on 
individuals and society.1 It may lead to dependence, which is best conceptualised 
XVLQJD³FKURQLFGLVHDVH´PRGHOeffective treatments are available, but illness is often 
characterised by relapses, remissions, and risk of premature death.2 3 
Across Europe, four trends are noteworthy: a decline in the use of intravenous 
heroin, a rise in the use of high potency synthetic opioids (for example, fentanyl), a 
rise in opioid related deaths, and an increase in the number of long term opioid users 
aged over 40.4 7KHZLGHO\UHSRUWHG³HSLGHPLF´RIRSLRLGDVVRFLDWHGGHDWKVLQWKH86
and Canada is also of global concern and has been attributed to under-regulated 
medical prescribing of high potency synthetic opioids and a growth in internet supply 
chains.5-7 Concurrent use of other substances, for example, alcohol, cocaine, 
benzodiazepines, neuropathic agents, and novel drugs such aV³VSLFH´LQFUHDVHVWKH
risk of adverse outcomes of opioid use in all settings.8-10 
In this review we describe an evidence based collaborative approach to caring for 
people who are dependent on illicit opioids (heroin or synthetic opioids) and related 
harms of use and who seek help for their dependence.11-13  
Approach to assessment and management 
The approach we describe consists of four phases: comprehensive assessment, 
decision making that is shared with the patient, keyworker-led psychosocial 
interventions, and peer-OHGVXSSRUW³PXWXDODLG´WRPLQLPLVHKDUPWRWKHLQGLYLGXDO
and community (fig 1). Distilling the current evidence base is challenging, 
particularly for psychosocial interventions, because of the socio-political and cultural 
contexts of illicit opioid use and heterogeneity of study design, interventions, and 
outcomes.  
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Fig 1 A four phase approach to assessment and management[Please supply a caption/title for this 
figure.] 
Phase 1: assessment 
An initial assessment may take place in a specialist drug and alcohol service or in 
a general practice clinic as an integrated public health commissioned service. The 
approach is also helpful for a patient seeking help for their opioid use  in routine 
general practice settings and enables a GP to assess dependence, advise on harm 
minimisation interventions and refer onwards to access treatment including 
psychosocial interventions. . The initial assessment is best conducted as a semi-
structured consultation to identify nature and pattern of substance use.  
Assess whether the patient meets the criteria for opioid dependence (box 1). 
Explore their physical and psychosocial needs, and those of carers and children.16-18 
Offer a non-judgmental, supportive attitude towards the patient to build a trustworthy, 
respectful, and sustainable therapeutic relationship.19 
Older, long-term users of illicit opioids typically have life-limiting multimorbidity 
(box 2) and are high users of unscheduled care.56-58 Co-location of treatment services 
for blood borne viruses (BBV) can improve the rates of uptake and completion of 
treatment for the BBV. 59 
Box start 
Box 1 The ICD-10 diagnostic criteria for opioid dependence (adapted from 
current guidelines)15 
Opioid dependence does not develop without a period of regular use, although regular 
use alone may not induce dependence. A definitive diagnosis of dependence should 
usually be made only if three or more of the diagnostic criteria have been experienced 
or exhibited concurrently at some time during the previous 12 months 
1. A strong desire or sense of compulsion to take opioids. 
2. Difficulties in controlling opioid use behaviours in terms of the onset, termination, 
or levels of use. 
3. A physiological withdrawal state when opioid use has ceased or been reduced, as 
evidenced by one of the following: 
a) characteristic withdrawal syndrome (hot/cold sweats, abdominal cramps, etc.) 
b) use of opioids (or closely related substances) with the intention of relieving or 
avoiding withdrawal symptoms 
c) evidence of tolerance, such that increased doses of opioids are required to 
achieve effects originally produced by lower doses. 
4. Progressive neglect of alternative pleasures or interests because of opioid use; 
increased amounts of time spent obtaining opioids or recovering from their effects 
5. Persisting with opioid use despite clear evidence of overtly harmful consequences, 
such as depressive mood states consequent to periods of heavy substance use, or 
drug related impairment of cognitive functioning. 
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Box end 
History of substance use 
7HOOPHZK\\RX¶YHFRPHWRGD\DQGZKDW\RXH[SHFWIURPWUHDWPHQW" [Is this 
assuming they have come seeking treatment? What if they are in contemplative stage 
or have not confirmed their substance use?] Explore motivating factors, treatment 
goals, support networks (such as the Drug Rehabilitation Requirement mandated by 
the UK criminal justice system). 
Tell me about the drugs that you currently use and how you prefer to take your 
drugs? This will help us work out the best care plan together. Ask about recent opioid 
use, current symptoms of withdrawal or intoxication, and duration of use. Assess the 
SDWLHQW¶VOHYHORIRSLRLGdependence and ask about use of other substances and route 
of administration (intravenous drug use, inhalation, sharing of drug equipment). 
Have you had treatment before for your drug problem? What did or GLGQ¶W
work? 
How much are you currently spending and how do you pay for your drugs? This 
may uncover criminality, abuse, trafficking, or forced sex work. 
Have you any concerns about your sexual health? Do you need contraception? 
Are you planning pregnancy? 
Medical history 
Are you taking any other medication? Do you have any health problems? Health 
disorders associated with illicit drug use are summarised in box 2. 
$VVHVVPHQWDOKHDOWKWDNLQJLQWRDFFRXQWWKHSHUVRQ¶VFXUUHQWPRRGDQG
evidence of psychosis or confusion; assess risk of self-harm. 
Box start 
Box 2 Health disorders and social issues associated with dependent illicit opioid 
use 
Acute physical disorders 
2YHUGRVHDQGIDWDOLW\ 
$FXWHEORRGERUQHYLUXVLQIHFWLRQ 
9DVFXODUDFXWHhaemorrhage from arterial access and damage, venous 
thromboembolism, arterial embolism and aneurysm 
3XOPRQDU\HPEROXVYHQRXVWKURPERHPEROLVP 
6HSVLV 
9LROHQWLQMXU\IUDFWXUHV 
$FXWHDVWKPD 
Chronic physical, sexual, and reproductive health disorders 
Multiple comorbidities 
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9DVFXODUUHFXUUHQWYHQRXVWKURPERHPEROLVPFKURQLFYHQRXVXOFHUDWLRQSHULSKHUDO
vascular disease 
$PSXWDWLRQVHFRQGDU\WRDUWHULDOYHQRXVLQVXIILFLHQF\LQIHFWLRQODFNRIVHOI-care 
6NLQFKURQLFSUXULWXVZRXQGLQIHFWLRQVFhronic lower limb ulceration 
*DVWURLQWHVWLQDOFKURQLFFRQVWLSDWLRQQDXVHD 
&KURQLFEORRGERUQHYLUXVLQIHFWLRQKHSDWLWLV&%+,9$,'6 
/LYHUGLVHDVHEORRGERUQHYLUXVLQIHFWLRQDVVRFLDWHGFKURQLFKHSDWLWLVFLUUKRVLV
hepatocellular carcinoma 
5espiratory disease: early onset chronic obstructive pulmonary disease, uncontrolled 
asthma, pneumonia, TB20-22 
3RRUGHQWDOKHDOWKGHQWDOGHFD\DEVFHVVHVH[WUDFWLRQV 
6H[XDODQGUHSURGXFWLYHKHDOWKVXE-fertility, sexually transmitted infections, low 
testosterone in men, erectile dysfunction23 24 
3RRUSUHJQDQF\RXWFRPHVXQSODQQHGSUHJQDQF\SRRUQXWULWLRQODFNRI
periconceptual vitamins, late antenatal booking, missed influenza/pertussis 
vaccination, premature birth, intrauterine growth retardation, fetal addiction 
syndromes, maternal death 
Mental health 
'HSUHVVLRQDQ[LHW\GLVRUGHUSRVW-traumatic stress disorder 
6HOI-injury or suicide 
6HYHUHPHQWDOLOOQHVVFRPRUELGRUVXEVWDQFHLQGXFHGSV\FKRVHVSHUVRQDOity 
disorder, delusional disorder, bipolar disorder 
&R-dependence on alcohol and/or other substances 
Social issues 
3RYHUW\FKURQLFGLVDELOLW\DQGLPSDFWRQHPSOR\PHQWDQGKRXVHKROGLQFRPH 
,QWHUUXSWHGHGXFDWLRQDQGVNLOOVWUDLQLQJ 
'RPHVWLFviolence, family breakdown 
&KLOGVDIHJXDUGLQJLVVXHV³ORRNHGDIWHU´FKLOGUHQVDIHJXDUGLQJUHJLVWUDWLRQ
FKLOGUHQ¶VDFFHVVWRGUXJVDQGDFFLGHQWDORYHUGRVHREVHUYLQJGUXJXVHEHKDYLRXUV 
$GXOWVDIHJXDUGLQJH[SORLWDWLRQVH[ZRUNYXOQHUDEOHDGXOWVKuman trafficking 
&ULPLQDOLW\GUXJUHODWHGWKHIWYLROHQFHKRPLFLGH 
Box end 
Social history 
:KHUHZKRGR\RXOLYHZLWK" ,QTXLUHDERXWWKHSHUVRQ¶VDFFRPPRGDWLRQDQG
whether they have a partner or anyone who can support them. Ask whether their 
partner or other household members use drugs or alcohol, and whether they feel safe. 
Are there children at home or elsewhere? Children might be living with a 
UHODWLYHRULQDVWDWXWRU\FDUHVHWWLQJ³ORRNHGDIWHU´RUDGRSWHGLQZKLFKFDVHDVN
about contact arrangements. Ask the ages and names of the children and explore the 
impact of drug use on parenting and social functioning (routines for children 
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including school attendance, physical or dental health checks), and safe storage of 
medication. Discuss safeguarding referral according to identified needs 18 
What jobs, training, and education have you done since school? 
How are you managing for money? Ask about employment, benefits, and debt. 
Are you at risk of harm from anyone? This might include physical, emotional, or 
sexual abuse by a family member or intimate partner. Consider use of screening tools, 
such as HARK. 25 26 
Routine physical assessment and tests 
Observe the person for evidence of opioid use, which might include intoxication 
and withdrawal symptoms (for example, hot or cold sweats, abdominal cramps).27 
Examine injecting sites. Undertake urine or saliva tests for opioids and other 
substances (according to local protocols) to confirm the presence or absence of drugs 
before initiating opioid agonist treatment. Offer testing for hepatitis A, B, C, and HIV 
(pre-testing is not a barrier to immunisation for hepatitis A and B). Further physical 
assessment may be undertaken based on clinical judgement. 
Phase 2: agreeing a treatment plan 
The aim of care is to integrate pharmacological and psychosocial treatments to 
EXLOGWKHSHUVRQ¶VUHVLOLHQFHKHDOWKDQGZHOOEHLQJ 
VWDELOLVHWKHLUHQYLURQPHQWDQG 
UHGXFHWhe risk of relapse to illicit opioid use.28 
,GHQWLI\WKHSHUVRQ¶VJRDOVGHVFULEHWKHWUHDWPHQWVDYDLODEOHDGGUHVVFRQFHUQV
and expectations, and give them time to consider treatment options. Consider the 
SHUVRQ¶VPRWLYDWLRQWRFKDQJH<RXPD\ZLVKWRDSSly a transtheoretical model of 
behaviour change (box 3).30 7KH³DFWLRQ´VWDJHLQWKLVPRGHO 
which includes engagement with a treatment plan (and re-engagement if relapse 
occurs), is key to effective care, as patient outcomes improve with length of time in 
treatment.14 
Box start 
Box 3 Stages of change²the transtheoretical model of behaviour change 
(adapted)29 
1. Precontemplation²has no intention to change behaviour, even when knowing that 
they have a problem (and thinks others are exaggerating their problem) 
2. Contemplation²is more consciously aware of the problem (pros and cons) and 
develops intentions to change over a period of time 
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3. Preparation²expresses intention and shows preparation to act, usually over the 
next month or more 
4. Action²Engages in a treatment plan and psychosocial support 
5. Maintenance²continues with health behaviour change over the next few years23 
Box end 
Drug treatment 
There are three usual treatment pathways: opioid agonist treatment, opioid 
assisted withdrawal treatment, and opioid antagonist maintenance. Opioid agonist 
treatment is considered first line treatment globally.  If taking this approach, the 
SUHVFULEHUVKRXOGDVFHUWDLQWKHSDWLHQW¶VUHVSRQVHVWRSUHYLRXVPHGLFDWLRQWKHOHYHORI
physical dependence, opioid tolerance, and their personal preference.31-33  
Opioid agonist treatment 
Calculation and titration of opioid agonist treatment dosage is subject to local 
protocols, with the aim of assisting the person to stop the use of illicit opioids and 
safely initiate opioid agonist treatment. Using an adequate and responsive 
replacement dosage regimen substantially improves outcomes, facilitates recovery, 
and reduces risk of overdose.34 Conversely, starting at too low a replacement dose 
reinforces withdrawal challenges and fatalism.35 Drug treatment services usually 
monitor supervised opioid agonist treatment and pharmacies dispense the drug.36 
A systematic review reported a substantial reduction in the risk for all cause and 
overdose mortality in people dependent on opioids who were undergoing opioid 
agonist treatments. 37 Pooled all-cause mortality rates were 11.3 and 36.1 per 1000 
person years in and out of methadone treatment (unadjusted out-to-in ratio 3.20, 95% 
confidence interval 2.65 to 3.86), and were reduced to 4.3 and 9.5 in buprenorphine 
treatment (2.20, 1.34 to 3.61).37 Retention in opioid agonist treatment is the strongest 
predictor of positive bio-psychosocial outcomes, with buprenorphine treatment being 
associated with lower mortality rates than methadone treatment.14 
Methadone, a long-acting mu-receptor agonist, usually blocks opioid withdrawal 
for 24 hours, removing the drive to use drugs. An adequate daily dose increases 
tolerance, making illicit opioid use less reinforcing. Induction involves careful 
titration with intensive, frequent monitoring to minimise risk of overdose. Once the 
dose of oral methadone is stabilised within a therapeutic range, the prescriber 
PDLQWDLQVRUJUDGXDOO\UHGXFHVWKHGRVDJHDFFRUGLQJWRWKHSDWLHQW¶VJRDO$V
methadone has no ceiling effect, it can lead to overdoses when it is used at doses 
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DERYHDSDWLHQW¶VWROHUDQFHRUZKHQLWLVFRPELQHGZLWKRWKHUFHQWUDOQHUYRXVV\VWHP
depressants (for example, alcohol, benzodiazepines, or other opioids). Perform an 
electrocardiogUDPLISUHVFULELQJ!PJRUDOPHWKDGRQHLIWKHSDWLHQW¶VKLVWRU\
suggests arrhythmia, or there is a family history of prolonged QT interval.34 
Sublingual buprenorphine is a partial mu-receptor agonist that partially blocks 
the action of opioid agonists (for example, heroin) and so discourages illicit opioid 
use. Buprenorphine is titrated to a therapeutic dose and may be prescribed for short or 
long term opioid agonist treatment. To minimise the risk of diversion to injection use, 
buprenorphine can be prescribed in a formulation that includes naloxone 
³VXER[RQH´DVKRUWDFWLQJRSLRLGDQWDJRQLVWWKDWKDVSRRUELRDYDLODELOLW\ZKHQ
sublingually administered, but blocks buprenorphine effects if injected.12 35 
Buprenorphine has lower lethality than methadone but can still be lethal when 
combined with other central nervous system depressant substances.38 Methadone has 
been available for opioid agonist treatment much longer than buprenorphine or 
suboxone and has the most comprehensive evidence of efficacy. Flexible dose opioid 
agonist treatment with methadone leads to greater retention in treatment than does 
sublingual buprenorphine.39 
Opioid assisted withdrawal treatment 
:LWKGUDZDOWUHDWPHQWPD\EHRIIHUHGLIWKHSDWLHQW¶VJRDOLVDEVWLQHQFHIURP
opioids. This regimen involves initial opioid agonist treatment and gradual reduction, 
followed by an out- or inpatient withdrawal programme according to local protocols 
DQGWDLORUHGWRLQGLYLGXDOFLUFXPVWDQFHV/RIH[LGLQHDQĮD-adrenergic receptor 
agonist, may be used to suppress withdrawal symptoms for a patient making a 
clinically supported, informed decision not to use opioid agonist treatment for 
withdrawal or with mild dependence.40 
Opioid antagonist maintenance (naltrexone) 
Naltrexone is an opioid antagonist that blocks or reverses the action of opioid 
agonists and so discourages illicit opioid use. Immediate release naltrexone is cost 
effective but patients report poor adherence compared with the extended release 
formulation.41 
Phase 3: support for behaviour change 
Psychosocial interventions are widely used to support a change in drug-related 
behaviours, although uptake and availability varies with treatment setting.12 42 There 
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DUHWZRFDWHJRULHVRILQWHUYHQWLRQLQWHQVLW\³VWDQGDUG´DQG³HQKDQFHG´FDUH%RWK
care pathways utilise a multi-agency, multidisciplinary approach.42 
In standard care, interventions offered by a keyworker include motivational 
interviewing and brief interventions, relapse prevention, goal setting, problem 
solving, and recovery planning. Motivational interviewing is an approach to support 
behaviour change in productive, person centred consultations.43 ³5HODSVHSUHYHQWLRQ
VWUDWHJLHV´DLPWRKHOSWKHSDWLHQWLGHQWLI\DYRLGDQGPDQDJHWULJJHUVWRGUXJXVHDQG
EXLOGUHVLOLHQFH³&RQWLQJHQF\PDQDJHPHQW´LVDFRQWURYHUVLDOEXWHIIHFWLYH
intervention whereby rewards, such as vouchers, are provided for positive behaviour 
change.44-46 
Enhanced care should be offered if there is poor response to standard care or for 
patients with more complex needs. A residential rehabilitation programme involves 
living within a therapeutic community over several months and typically includes 
high intensity cognitive behavioural therapy and 12 step approaches. Psychiatric 
comorbidities in opioid dependent patients far exceed those in the general population, 
influence outcomes, and should be treated according to guidelines.47 48 Patients with 
dual diagnoses should be offered integrated mental illness and substance abuse 
treatments, long term follow-up, and tailored psychosocial interventions.49 50 
Harm reduction 
For many patients, change is slow, and continuing IVDU is a challenge [meaning 
that they continue to use IV drugs?]. The aim is to support change to healthier 
behaviours, for example, safer use (inhaled use, avoiding solitary intravenous use, 
correct disposal of drug use equipment) and safer sexual health practices. Education, 
convenient access to sterile drug paraphernalia, and free condoms can reduce the risk 
of sepsis, transmission of blood borne virus, and venous thromboembolism. Offer 
immunisation for hepatitis A and B.14 51 
Emergency care for opioid overdose 
2IIHUDOOSDWLHQWVQDOR[RQH³WDNHKRPH´WUHDWPHQWNLWVDQGRIIHUFDUHUVWUDLQLQJ
in first response and administration.50-52 Those at highest risk are younger, male, older 
with physical/mental health comorbidities, users of intravenous drugs, or those 
recently discharged from prison.53 54 7KH³$%&'(´ILUVWUHVSRQVHLVHVVHQWLDOEXW
where an overdose is suspected, administer naloxone (provided in two-dose injection 
kits) and repeat as necessary while awaiting emergency services. The patient should 
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be monitored in an urgent care facility for a minimum of four hours.52 55 Consider 
other causes of collapse, such as overdose with other drugs, benzodiazepines, alcohol, 
and medical conditions such as seizure, sepsis, and head trauma. 
Phase 4: early recovery 
The key principle of early recovery is to promote stability by addressing health 
and social needs, recognising that the social determinants and bio-psychosocial 
outcomes of opioid dependence are interdependent.11 12 Stability is enhanced by 
adherence to opioid agonist treatment, regular contact with a keyworker, and 
addressing other needs, such as healthcare, housing, and safeguarding of children.12 18 
Aftercare programmes include mutual aid groups, education, training, and 
employment support to enhance self-esteem and self-efficacy. Independent support 
QHWZRUNVLQFOXGH³60$57´JURXSVDQG³1DUFRWLFV$QRQ\PRXV´ZKLFKRIIHUSHHU
support and build social capital to sustain recovery.12 
Box start 
Education into practice 
+RZPLJKWXVLQJWKHFKURQLFFRQGLWLRQPRGHORIFDUHIRUSDWLHQWVZKRXVHLOOLFLW
opioids affect how you consult? 
+RZPLJKW\RXLQFUHDVHSDWLHQWFDUHUDQGFRPPXQLW\OHYHOXSWDNHRIHGXFDWLRQ
and training in the management of overdose, including how to administer 
naloxone? 
Box end 
Box start 
How patients were involved in the creation of this article 
Neil Dolan has lived experience of enhanced care for opioid use and works in drug 
and alcohol services in primary care. 
Box end 
Box start 
Sources and selection criteria 
We reviewed national and international English language clinical management 
guidelines from the World Health Organization, the UK, the European Union, 
Canada, and the United States of America. In addition, we used the Cochrane 
database to identify relevant systematic reviews, undertook a PubMed search for 
relevant systematic reviews, and hand searched the guideline references for original 
research relevant to the clinical management approach to illicit opioid use. 
Box end 
Box start 
Areas for future research 
Would novel research methodologies (for example use of incentives or experience 
based co-design) optimise recruitment and address high attrition rates in 
intervention and cohort studies? 
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Which interventions improve outcomes of healthcare for physical-mental 
multimorbidity in the illicit opioid user and where should these interventions be 
provided? 
Are diversified opioid agonist treatment regimens (such as slow or immediate-release 
oral diacetylmorphine, inhaled opioid agonist treatment, or supervised injected 
heroin assisted treatment) cost effective and generalisable interventions? 
Box end 
Box start 
Online resources for patients who use illicit opioids and/or other substances 
Alcohol and drug misuse prevention and treatment guidance. www.gov.uk 
WHO²Treatment of opioid dependence. www.who.int 
Get help with problematic substance use. www.canada.ca 
Addiction and dependency. www.mind.org.uk 
Substance abuse and addiction²the essentials. www.militaryonesource.mil 
Choice of OAT: 
https://www.choiceandmedication.org/sabp/generate/handyfactsheetmethadonevs
buprenorphine.pdf 
Box end 
Box start 
Continuing medical education resources for healthcare professionals 
Principles of drug addiction treatment: a research-based guide (third edition). 
www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-
based-guide-third-edition/resources 
American Society of Addiction Medicine²resource links. 
www.asam.org/resources/public-resources/resource-links 
Opioid dependence. www.cks.nice.org.uk/opioid-dependence 
Standards and guidelines for practices. www.emcdda.europa.eu/best-
practice/standards/treatment 
Guidelines for the psychosocially assisted pharmacological treatment of opioid 
dependence. 
www.who.int/substance_abuse/publications/opioid_dependence_guidelines.pdf 
Box end 
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